Senseonics HoldingsSENS
SENS
About: Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Employees: 132
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $206K | Put options by funds: $125K
0% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 27
0.03% less ownership
Funds ownership: 11.11% [Q2] → 11.08% (-0.03%) [Q3]
2% less funds holding
Funds holding: 130 [Q2] → 128 (-2) [Q3]
12% less capital invested
Capital invested by funds: $23.5M [Q2] → $20.8M (-$2.78M) [Q3]
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
335%
upside
Avg. target
$2
335%
upside
High target
$2
335%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target | 335%upside $2 | Buy Reiterated | 15 Nov 2024 |
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Conference Call Participants Brian Langan - Morgan Stanley Vernon Bernardino - H.C. Wainwright Operator Good day, everyone, and welcome to the Senseonics Third Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
2 months ago
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management
Neutral
PRNewsWire
2 months ago
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia Diabetes Care underway with a new campaign to highlight the unique benefits of having just one CGM for one full year GERMANTOWN, Md. and ST. LOUIS , Oct. 10, 2024 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Mercy, a leading healthcare system, today announced that the first commercial patient received the next-generation Eversense® 365 CGM system.
Neutral
GlobeNewsWire
2 months ago
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older
Neutral
Business Wire
2 months ago
Eversense 365 Launches in the US: One Year. One CGM.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's only One Year CGM, to people with diabetes in the U.S.ii Developed by Senseonics Holdings, Inc. (NYSE American: SENS), Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of li.
Neutral
Zacks Investment Research
2 months ago
Senseonics Stock Down Despite New FDA Approval for Eversense 365
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Neutral
GlobeNewsWire
3 months ago
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes
Neutral
Business Wire
3 months ago
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, today announced that the US Food and Drug Administration (FDA) has cleared the next-generation Eversense® 365 CGM system for people with Type 1 and Type 2 diabetes aged.
Neutral
GlobeNewsWire
3 months ago
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, being held in New York, NY.
Charts implemented using Lightweight Charts™